Opioid antagonists such as naltrexone act by blocking µ-opioid receptors, potentially modulating the dysregulated endogenous opioid system implicated in DPDR pathophysiology. By competitively inhibiting opioid receptor binding, these medications may help reduce depersonalization and derealization symptoms through neurotransmitter rebalancing and alterations in interoceptive processing.